Clazakizumab
- Generic Name
- Clazakizumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1236278-28-6
- Unique Ingredient Identifier
- 4S38Z8RA9O
- Background
Clazakizumab has been used in trials studying the treatment of Rheumatoid Arthritis.
- Associated Conditions
- -
- Associated Therapies
- -
Phase 3 trial assesses clazakizumab in kidney transplant recipients with caAMR
Clazakizumab failed to meet primary efficacy outcomes in the IMAGINE Phase 3 trial for chronic active antibody-mediated rejection (caAMR) in kidney transplant recipients, showing no difference in eGFR change from baseline at week 52 compared to placebo, with no safety concerns observed.
Trial assesses antibody therapy for chronic a
Clazakizumab, targeting IL-6, failed to meet primary efficacy outcomes in the IMAGINE Phase 3 trial for chronic active antibody-mediated rejection in kidney transplant recipients, according to a final analysis. No significant difference in kidney function was observed between clazakizumab and placebo, with no safety concerns reported.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath